Comparison of immunogenicity of monovalent inactivated influenza vaccine contained Saitama strain with it contained Hong Kong strain

Comparison of immunogenicity of monovalent inactivated influenza vaccine contained Saitama strain with it contained Hong Kong strain - Comparison of immunogenicity of monovalent inactivated influenza vaccine contained Saitama strain with it contained Hong Kong strain

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029293

Enrollment

100

Registered

2017-09-26

Start date

2017-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of influenza

Interventions

Subcutaneous injections of monovalent inactivated influenza vaccine contained Saitama strain (0.5mL) into subjects arms Subcutaneous injections of monovalent inactivated influenza vaccine contained Ho

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects who; 1. Provide written consent 2. Male or Female over 20 years old. 3. Are not vaccinated 2017-18 seasonal influenza vaccine. 4. Do not plan to get vaccinated seasonal influenza vaccine until completion of blood sample collection scheduled 3 weeks after vaccination.

Exclusion criteria

Exclusion criteria: Subjects who; 1. have fever. 2. have sever acute disease 3. are allergic to substance of study vaccine, eggs, chicken, or any derivative of chicken . 4. are vaccinated live vaccine within 27 days, or inactivated vaccine within 6 days. 5. are judged not appropriate for this study by study physician.

Design outcomes

Primary

Measure	Time frame
1, Immunogenicity Antibody titer against study vaccine strains and circulated strains	—

Secondary

Measure	Time frame
2. Safety Adverse event and side effect occurred within one week after vaccination.	—

Countries

Japan

Contacts

Public ContactHiroko Kumashiro

SOUSEIKAI Hakata Clinic Planning & Coordination Dept.

hiroko-kumashiro@lta-med.com0922837701

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026